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Abstract
Background: Salmonella causes acute systemic inflammation by using its virulence factors to invade the intestinal
epithelium. But, prolonged inflammation may provoke severe body catabolism and immunological diseases. Salmonella has
become more life-threatening due to emergence of multiple-antibiotic resistant strains. Mannose-rich oligosaccharides
(MOS) from cells walls of Saccharomyces cerevisiae have shown to bind mannose-specific lectin of Gram-negative bacteria
including Salmonella, and prevent their adherence to intestinal epithelial cells. However, whether MOS may potentially
mitigate systemic inflammation is not investigated yet. Moreover, molecular events underlying innate immune responses
and metabolic activities during late inflammation, in presence or absence of MOS, are unknown.
Methods and Principal Findings: Using a Salmonella LPS-induced systemic inflammation chicken model and microarray
analysis, we investigated the effects of MOS and virginiamycin (VIRG, a sub-therapeutic antibiotic) on innate immunity and
glucose metabolism during late inflammation. Here, we demonstrate that MOS and VIRG modulated innate immunity and
metabolic genes differently. Innate immune responses were principally mediated by intestinal IL-3, but not TNF-a, IL-1 or IL-
6, whereas glucose mobilization occurred through intestinal gluconeogenesis only. MOS inherently induced IL-3 expression
in control hosts. Consequent to LPS challenge, IL-3 induction in VIRG hosts but not differentially expressed in MOS hosts
revealed that MOS counteracted LPS’s detrimental inflammatory effects. Metabolic pathways are built to elucidate the
mechanisms by which VIRG host’s higher energy requirements were met: including gene up-regulations for intestinal
gluconeogenesis (PEPCK) and liver glycolysis (ENO2), and intriguingly liver fatty acid synthesis through ATP citrate synthase
(CS) down-regulation and ATP citrate lyase (ACLY) and malic enzyme (ME) up-regulations. However, MOS host’s lower energy
demands were sufficiently met through TCA citrate-derived energy, as indicated by CS up-regulation.
Conclusions: MOS terminated inflammation earlier than VIRG and reduced glucose mobilization, thus representing a novel
biological strategy to alleviate Salmonella-induced systemic inflammation in human and animal hosts.
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Introduction
Salmonella is a leading human food-borne pathogen, worldwide
[1]. The pathogen invades the intestinal epithelium by using its
specialized Type III secretory systems (T3SS) to cause acute
systemic or extra-intestinal inflammation [2]. Indeed, the intestine
is the portal of entry through which Salmonella triggers systemic
infections. However, although life-threatening, treatment of
Salmonella-induced systemic inflammation has received very little
interests in scientific investigations. The disease is frequently
caused by consumption of undercooked contaminated poultry
meat and meat products [3], which accidentally occur upon
exposure to intestine-residing Salmonella during chicken processing.
Over decades, low doses of sub-therapeutic antibiotics such as
virginiamycin (VIRG) have been administered daily in diets of
food-producing animals, including poultry, to control intestinal
pathogens. Unlike therapeutic antibiotics, sub-therapeutic antibi-
otics are macromolecules that exert localized bactericidal effects in
the intestines only. However, according to the World Health
Organization (WHO), such practice has debatably been associated
with emergence of multiple antibiotic-resistant strains of Salmonella
[4]. Today, not only has Salmonella become more difficult to
control in poultry production, but antibiotic treatment of
Salmonella-induced gastrointestinal and systemic infections has
become less successful among hospitalized patients, causing higher
death rates [1], [4]. Therefore, the development of natural
immuno-modulators that can prevent or treat Salmonella infections
in both poultry and humans is highly desirable. Evidence exist that
mannose-rich oligosaccharides (MOS), purified from cells walls of
Saccharomyces cerevisiae, competitively binds mannose-specific lectin,
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fimbriae, including Salmonella, thereby reducing their adherence to
mannose-containing glycoprotein receptors on intestinal epithelial
cells in humans and chickens [5], [6].
Innate immunity represents the first line of immune defense
against invading pathogens in both mammals and avian species.
Extracellular Toll-like receptor 4 (TLR-4) of innate immune cells,
including macrophages and dendritic cells, recognizes the LPS-
endotoxin in outer membranes of Gram-negative bacteria [7]. The
engagement of LPS to TLR-4 triggers a cascade of transduction
signaling resulting in inflammatory responses characterized by
secretion of pro-inflammatory cytokines, including IL-1 and IL-6
that orchestrate pathogen clearance [8]. But, innate immune
responses must be regulated exceptionally tightly because high IL-1
and IL-6 levels cause fever, anorexia and bodyweight (BW) losses
[9,10], catabolism of skeletal muscles [11–13] and adipose tissues
[14],andimmunologicaldiseases[15] inchickens,ratsandhumans.
Therefore, it is clear that an ideal immune response would be one
that can clear pathogens or antigens and be terminated soon after
infection. However, despite significant advances in our understand-
ing about inflammatory responses, molecular events of innate
immunity and metabolic activities during the period of late
inflammation are still not clear. Moreover, whether modulation of
intestinal mucosal immunity due to dietary MOS may suppress
Salmonella-induced systemic inflammation and reduce nutrient
mobilization is unknown. The regulatory immune responses
between intestinal mucosal and systemic immunity is well
recognized [16], [17]. Therefore, considering the human health
havoc due to sub-therapeutic antibiotic utilization among food-
producinganimals, this study evaluatedthe effects of MOS and sub-
therapeutic antibiotics on innateimmunity andnutrientmetabolism
during late Salmonella LPS-induced systemic inflammation.
The experiment reported herein, conducted in a chicken model,
a frequently utilized biological model in nutrigenomic scientific
investigations [18], and using chicken-specific microarrays, reveals
that MOS and the VIRG antibiotic differently regulated
expressions of genes involved in innate immunity and metabolic
pathways during late systemic inflammation. Innate immune
responses were principally mediated by intestinal IL-3, but not IL-
1 or IL-6. In contrast to VIRG, MOS inherently induced innate
immune responses in non-challenged control hosts. Interestingly,
however, MOS terminated innate immune responses earlier than
VIRG and reduced glucose mobilization.
Results
LPS induced pathological symptoms, reduced feed intake and
BW, and increased liver size in MOS- and VIRG-fed chickens.
However, to make a clear distinction between the effects of MOS
and VIRG among hosts within the physiological (non-challenged
controls) and inflammatory (LPS-challenged) conditions, we relied
on microarray results that detailed the coordinately regulated
biological mechanisms underlying innate immunity and nutrient
metabolism. Tissue-specific RNA extracted from the intestines,
liver and skeletal muscles at 24 h post-LPS challenge were
analyzed using chicken-specific microarrays. All data files from
this experiment have been deposited into the MIAME compliant
Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.
gov/projects/geo (accession no. GSE28959).
LPS induced clinical symptoms in antibiotic- and MOS-
fed chickens
To provoke a systemic inflammatory response, chickens were
injected i.p. with a sublethal dose of LPS (3 ml of 100 mg LPS/L).
ThereactiontoLPSisawell-characterized innateimmuneresponse
[19]. Whether hosts were fed MOS or VIRG, LPS caused
symptoms of drowsiness, lethargy, ruffled feathers, moderate
diarrhea, starvation and withdrawal from water at 6 h post-LPS
injection, thus demonstrating success of our challenge model. These
clinical signs of innate immune response were most evident around
8 h after LPS injection. Clinical and behavioral changes due to LPS
injection have previously been reported in different animal species,
including chickens [9]. No signs of inflammatory responses were
observed among non-challenged control hosts. To assess patholog-
ical changes further, body temperatures were measured at 0, 2, 4, 6,
8, 12, 24 and 48 h post-LPS injection. Body temperature was
similar among all hosts prior (0 h) to LPS challenge (Figure S1A).
But, LPS markedly increased body temperatures of MOS- and
VIRG-fed hosts after 4 h of LPS challenge, and this effect persisted
through 24 h (Figure S1A and B). After 48 h, however, all hosts
regained their homeostatic state after termination of inflammatory
responses (Figure S1A and B).
LPS reduced feed intake and bodyweight gain, and
increased liver weight in antibiotic- and MOS-fed
chickens
LPS markedly reduced feed intake at 12 h (Figure S2A), but not
at 24 and 48 h, post-challenge despite VIRG and MOS
supplementations. In addition, LPS’s effects in reducing feed
consumption and inducing profuse diarrhea at 12 h led to severe
loss in BW gain (growth) (Figure S3A and C). However, depressed
BW gain persisted through 24 and 48 h post-LPS challenge. On
the other hand, increased liver weights were observed at 12 and
24 h among LPS-challenged hosts (Figure S4A and C). But, the
more profound increase in liver weights that occurred after 12 h
rather than 24 h (+0.66% vs +0.40% of BW) indicated that higher
liver metabolic activities might have occurred at 12 h post-LPS
challenge responsive to host’s higher energy demands. Moreover,
given the similarities in body temperatures, feed intake, and liver
weights between LPS-challenge and non-challenge control hosts, it
is clear that inflammatory responses were abated at 48 h post-LPS
challenge. All of these findings indicated that inflammatory
responses were more intense earlier than 24 h post-LPS challenge.
Therefore, based on the similarity in feed intake, depressed growth
and increased liver weights, but persistence in elevated body
temperatures, we concluded that 24 h post-LPS treatment
corresponded to late inflammation.
Main Effects: LPS increased innate immune responses
Our results revealed that LPS significantly increased innate
immune responses in intestinal tissues (Table 1) characterized by
IL-3 up-regulation, and down-regulation of the gene for zinc
finger CCCH-type containing 15 (ZC3H15), which negatively
regulates macrophage activation [20]. Additionally, the gene
coding for the signal transducer and activator of transcription 2
(STAT2), a signaling pathway that augments macrophage’s
phagocytic activities against pathogenic bacteria by inducing
inducible nitric oxide synthase (iNOS) and lysosomal enzymes
[21], was induced in the liver. But, down-regulation of genes were
observed for TLR 2 precursor (TLR2-2) that also recognizes and
binds LPS [22], gallinacin-1 alpha (Gal-1), a wide spectrum
antimicrobial peptide functionally equivalent to human b-
defensins [23], and putative CXCR1, an IL-8 receptor that binds
the IL-8 chemoattractant expressed by macrophages, monocytes
and neutrophils. Indeed, gene expression for 29–59-oligoadenylate
synthetase A (OAS
*A), which is involved in viral RNA cleavage
inhibiting IFN-c-mediated viral infections [24], was intestinally
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differential immune gene expressions as observed in the intestines
and liver were not detected in muscle tissues.
Main Effects: LPS increased glucose mobilization and
modified fatty acid metabolism
During acute inflammation, starvation alters host’s carbohy-
drate, protein and fat metabolisms that are orchestrated by
synergistically-operated pro-inflammatory cytokines, to meet the
body’s energy requirements. Subsequent to rapid glucose absorp-
tion and oxidative utilization, blood glucose level is maintained by
liver glycogenolysis, catabolism of skeletal muscles that generates
and mobilizes amino acids for liver gluconeogenesis [12], [13], and
catabolism of adipose tissues that triggers liver lipolysis [14].
However, here, we observed that glucose mobilization occurred
differently during late inflammation than during immunologically
non-challenged conditions. LPS significantly increased intestinal
gluconeogenesis by increasing gene expression for phosphoenol-
pyruvate carboxykinase 1 (PEPCK), a key gluconeogenic enzyme
that synthesizes phosphoenolpyruvate from oxaloacetate (Table 1).
Evidently, intestinal glycolysis and cholesterol synthesis were
repressed as indicated by gene down-regulations for phosphopy-
ruvate hydratase (ENO2), which converts 2-phosphoglycerate into
phosphoenolpyruvate, and 3-hydroxy-3-methylglutaryl-CoA re-
Table 1. Genes identified as differentially expressed due to main LPS effects
1.
Gene Gene symbol Gene ID Fold change P-value Gene regulation by LPS
2
Intestine
Immune response
Interleukin 3 IL-3 474356 1.03 0.00328 +
Toll-like receptor 2 precursor TLR2-2 769014 0.98 0.00596 2
Zinc finger CCCH-type containing 15 ZC3H15 423992 0.98 0.03575 2
29–59 oligoadenylate synthetase A OAS*A 395908 0.96 0.02579 2
Gallinacin-1 alpha Gal-1 395841 0.99 0.09106 2
Metabolism
Phosphoenolpyruvate carboxykinase 1 PEPCK 396458 1.05 0.00497 +
Phosphopyruvate hydratase ENO2 395689 0.94 0.00018 2
3-hydroxy-3-methylglutaryl-CoA reductase HMGCR 395145 0.95 0.00004 2
Others
Myosin, heavy polypeptide 7, cardiac muscle MYH7 395350 1.03 0.01938 +
Actin alpha 2, smooth muscle, aorta ACTA2 423787 0.98 0.04217 2
Myosin light polypeptide 9 regulatory MYL9 396215 1.04 0.02469 +
Liver
Immune response
Signal transducer and activator of
transcription 2
STAT2 6773 1.04 0.00018 +
Putative CXCR1 isoform I and II
(IL-8 receptor)
CXCR1 430652 0.97 0.02406 2
Metabolism
Enoyl-CoA hydratase EHHADH 424877 1.05 0.00017 +
Protein phosphatase 1 PPP1R8 419564 1.03 0.00818 +
Malic enzyme 1 ME 374189 1.03 0.03684 +
59-AMP-activated protein kinase
gamma-2
PRKAG2 420435 1.03 0.00190 +
Others
Deiodinase Type 2 DIO2 373903 0.95 0.00043 2
Iroquois homeobox protein 1 IRX1 374185 1.05 0.00136 +
Potassium voltage-gated channel
shaker-related subfamily No 3
KCNA3 404303 1.06 0.00008 +
Skeletal muscle
Metabolism
6-phosphofructokinase (PFK-1) PFKM 374064 0.95 0.00001 2
Others
Atrial natriuretic factor precursor NPPA 395765 1.03 0.00005 +
1Pooled LPS-challenged hosts: MOS+VIRG (antibiotic) groups; The complete raw data have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.
nlm.nih.gov/projects/geo (accession no. GSE28959).
2+: up-regulated genes by LPS; 2: down-regulated genes by LPS.
doi:10.1371/journal.pone.0030323.t001
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mevalonate pathway converting 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) into mevalonate [25], respectively. The high rates of
glucose synthesis and glucose trafficking across intestinal epithelial
cells enhanced intestinal contractions as indicated by myosin heavy
polypeptide 7 cardiac muscle (MYH7) and myosin light polypeptide 9
regulatory (MYL9) up-regulations [26]. Contrary to expectations,
gluconeogenesis did not occur in the liver. Intriguingly, LPS up-
regulated genes coding for malic enzyme (ME), a key enzyme
involved in fatty acid synthesis catalyzing the oxidative decarbox-
ylation of malate to pyruvate, NADPH and carbon dioxide [27],
and enoyl-CoA hydratase (EHHADH), a key enzyme involved in
b-oxidation of fatty acids [28]. Therefore, metabolic energy to
support late inflammation was derived mostly from increased fatty
acid de-novo biosynthesis followed by its catabolism. Unexpectedly,
LPS up-regulated gene for 59-AMP-activated protein kinase
gamma 2 (PRKAG2), a low energy sensor that represses acetyl-
CoA carboxylase and HMG-CoA reductase to inhibit fatty acid
and cholesterol biosynthesis, respectively [29]. In muscle tissues,
down-regulation of the gene for 6-phosphofructokinase (PFKM), a
regulatory enzyme that converts fructose-6-phosphate into fruc-
tose-1,6-biphosphate, suppressed the glycolytic pathway, whereas
atrial natriuretic factor precursor (NPPA) up-regulation caused vasodi-
latation to increase blood flow [30]. Taken together, all these
findings reveal a clear disassociation between glucose mobilization
and the biosynthesis and b-oxidation of fatty acids. These
discrepancies could be attributed to MOS’s immune-stimulatory
effects among non-challenged control hosts, as discussed later.
MOS increased innate immune responses in non-
challenged control chickens
Because MOS increases Salmonella and E. coli clearance of the
intestines [5], we thought that MOS may suppress innate immune
responses under inflammatory conditions rather than VIRG
thereby reducing catabolism of body reserves. However, MOS
significantly increased innate immune responses among non-
challenged control hosts than VIRG. For instance, several innate
immune genes were induced by MOS in the intestines, including
IL-3, TLR-3, TLR2-2 and Gal-1 (Table 2). Moreover MOS up-
regulated liver genes for putative CXCR1, IL 13 receptor alpha 2
(IL13RA2), which is a specific IL-13 receptor, and CD3
glycoprotein (CD3), which increases T cell activation and signaling
of humoral immunity [31]. But, STAT2 was down-regulated.
MOS increased glucose mobilization and metabolism in
non-challenged control chickens
Augmentation in immune responses by MOS among non-
challenged control hosts significantly increased glucose mobilization
and metabolism. MOS down-regulated the gene for heat shock
protein 1 (HSPE1), which folds and activates newly synthesized
linear proteins into functional 3-D proteins [32]; thus, deactivated
proteins were increasingly utilized in intestinal gluconeogenesis as
mediated by PEPCK up-regulation (Table 2). Increased intestinal
contractions, in part due to increased glucose absorption across
epithelial cells, were mediated by MYH7 up-regulation but not
MYH11 and MYL9. Correspondingly, NPPA was up-regulated to
ascertain high glucose flux into the liver via the hepatic portal vein.
Therefore, to increase the glucose-uptake capacity of liver cells,
MOS induced the gene for deiodinase type 2 (DIO2), reported to
reduce insulin resistanceby increasing intracellular triiodothyronine
(T3) levels [33]. Furthermore, down-regulation of potassium voltage-
gated channel shaker-related subfamily 3 (KCNA3) significantly increased
insulin-stimulated glucose uptake through the GLUT4 glucose
transporter, as reported by [34]. As evidenced by ENO2 up-
regulation, high liver glucose increased liver glycolytic activities for
energy generation. ME and EHHADH down-regulations repressed
liver fatty acid biosynthesis and b-oxidation, respectively. There-
fore, elevated intestinal gluconeogenesis and liver glycolysis were
sufficient to meet the host’s energy demands.
LPS mediated innate immune responses differently
within MOS and antibiotic chicken groups
So far, we reported inherent immune-stimulatory effects due to
independent LPS and MOS treatments. Therefore, simultaneous
administration of these treatments was expected to intensify the
inflammatory responses. Interestingly, however, our results
revealed that MOS counteracted the detrimental effects of LPS
on innate immunity. Although we observed intestinal down-
regulation of the gene for IL-10, an anti-inflammatory cytokine
that causes negative-feedback on secretions of pro-inflammatory
cytokines [35], neither IL-3, as observed due to LPS (Table 1)
treatment alone, nor any other pro-inflammatory cytokines were
induced (Table 3). To further support MOS’s effect in alleviating
inflammatory responses, we observed down-regulations of TLR2-
2, TLR-3 and OAS
*A, and IL13RA2 and CD3 in intestinal and liver
tissues, respectively. In MOS-fed hosts, innate immune responses
after LPS challenge were principally mediated by ZC3H15 down-
regulation that enhanced macrophage activation. In VIRG hosts,
however, intestinal IL-3 and TLR-3 up-regulations (Table 4)
revealed higher LPS-induced inflammatory responses.
LPS mobilized energy differently within MOS and
antibiotic chicken groups
To further evidence that MOS reduced innate immune
responses, here we report that LPS failed to induce gluconeogen-
esis or any other major nutrient mobilization processes among
MOS-fed hosts (Table 3). Previously, however, we observed
increased intestinal gluconeogenesis due to LPS in the absence of
MOS (Table 1). These results, together with reduced liver glucose
uptake mediated by DIO2 down-regulation and KCNA3 up-
regulation, led us to believe that liver glucose levels were
sufficiently high to meet the host’s energy demands. However,
reduced glycolytic activities, due to ENO2 down-regulation,
demonstrated that liver glucose levels were abnormally low.
Intriguingly, despite reduced glycolysis, we observed up-regulation
of the gene for ATP citrate synthase (CS), which catalyzes citrate
synthesis from acetyl Co-A and oxaloactetate. Given that citrate is
the key regulatory substrate of the TCA cycle, our results indicated
that host’s energy demands were likely met mainly via the TCA
cycle. We also observed that glucose utilization for energy caused
down-regulation of UDP glucose pyrophosphorylase 2 (UGP2), which
reduces liver glycogen synthesis [36], whereas PRKAG2 up-
regulation repressed fatty acid and cholesterol biosynthesis.
Finally, MOS down-regulated the gene for a-actin 2 in intestinal
smooth muscles (ACTA2) that reduced intestinal contractions
[37], whereas MYH11 and MYL9 were up-regulated. Down-
regulation of HMGCR repressed intestinal cholesterol synthesis.
Contradictorily, despite VIRG supplementation, LPS challenge
profoundly increased gluconeogenesis, as indicated by PEPCK up-
regulation in the intestines (Table 4). Evidently, MYH7 was up-
regulated whereas ENO2 and HMGCR were down-regulated to
suppress intestinal glycolysis and cholesterol synthesis, respectively.
But, high glucose influx into the liver increased glycolytic activities
through ENO2 up-regulation. Therefore, glucose metabolites were
most increasingly utilized in TCA cycle for energy generation.
Surprisingly, CS was down-regulated and citrate was instead
Yeast Cell Wall Anti-Inflammatory Effects
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expressions of genes for ATP citrate lyase (ACLY), which catalyzes
citrate cleavage into acetyl Co-A and oxaloacetate [38], [39], ME
and fatty acid synthetase (FAS; as shown in Figure 1A). PFKM
down-regulation and NPPA up-regulation occurred in muscle
tissues of both MOS- and VIRG-fed hosts.
MOS increased innate immune responses in LPS-
challenged chickens
In comparisons to LPS-challenged hosts fed VIRG, the additive
immune stimulatory effects of LPS and MOS significantly
increased innate immune responses as demonstrated by intestinal
IL-3 up-regulation, and down-regulation of IL-10 and ZC3H15
(Table 5). But, TLR-3, the corresponding receptor to IL-3, was
repressed in the intestines. STAT2 was up-regulated in the liver.
MOS mobilized energy differently than antibiotic in LPS-
challenged chickens
Despite increased immune responses in LPS-challenged hosts
fed MOS, these chickens faced no detrimental nutrient mobiliza-
tion processes when compared to LPS-injected hosts fed VIRG.
Intestinal gluconeogenesis did not occur although newly-synthe-
Table 2. Genes identified as differentially expressed due to MOS in non-challenged control hosts
1.
Gene Gene symbol Gene ID Fold change P-value
Gene regulation by
MOS
2
Intestine
Immune response
Interleukin 3 IL-3 474356 1.05 2.98E-05 +
Toll-like receptor 3 TLR3 422720 1.04 0.00687 +
Toll-like receptor 2 precursor TLR2-2 769014 1.03 0.00984 +
29–59 oligoadenylate synthetase A OAS*A 395908 1.15 0.00000 +
Gallinacin-1 alpha Gal-1 395841 1.03 0.00145 +
Metabolism
Phosphoenolpyruvate carboxykinase 1 PEPCK 396458 1.11 0.00007 +
Others
Myosin, heavy polypeptide 7, cardiac muscle MYH7 395350 1.04 0.01797 +
Secreted protein acidic cysteine-rich SPARC 386571 0.94 0.00023 2
Myosin, heavy chain 11, smooth muscle MYH11 396211 0.87 0.00000 2
Heat shock 10 kDa protein 1 HSPE1 395948 0.90 0.00057 2
Myosin light polypeptide 9 regulatory MYL9 396215 0.93 0.00117 2
Atrial natriuretic factor precursor NPPA 395765 1.05 0.00005 +
Iron regulatory protein 1 IRP1 373916 0.92 0.00000 2
Liver
Immune response
Interleukin 13 Receptor Alpha 2 IL13RA2 422219 1.05 0.00002 +
Signal transducer and activator of transcription 2 STAT2 6773 0.97 0.02042 2
Putative CXCR1 isoform I and II (IL-8 receptor) CXCR1 430652 1.07 0.00018 +
CD3 glycoprotein CD3D 396518 1.04 0.00010 +
Metabolism
Enoyl-CoA hydratase EHHADH 424877 0.95 0.01192 2
Protein phosphatase 1 PPP1R8 419564 0.97 0.04035 2
Phosphopyruvate hydratase ENO2 395689 1.05 0.00362 +
Malic enzyme 1 ME 374189 0.96 0.05583 2
Others
Deiodinase Type 2 DIO2 373903 1.05 0.02708 +
Potassium voltage-gated channel shaker-related
subfamily No 3
KCNA3 404303 0.95 0.00649 2
Skeletal muscle
Others
NK2 transcription factor related locus 5 NKX2-5 396073 1.18 0.00000 +
Desmin DES 395906 0.89 0.00011 2
1Control hosts: MOS-fed chickens v/s VIRG-fed chickens; The complete raw data have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.
nih.gov/projects/geo (accession no. GSE28959).
2+: up-regulated genes by MOS; 2: down-regulated genes by MOS.
doi:10.1371/journal.pone.0030323.t002
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(Table 5). Again, our results about CS up-regulation demonstrate
that energy was essentially derived from increasingly synthesized
citrate in the liver. Under the effects of LPS, MOS repressed
glycogen synthesis by down-regulating UGP2; glycolysis by down-
regulating ENO2; fatty acids biosynthesis by down-regulating
Table 3. Genes identified as differentially expressed due to LPS within MOS-fed hosts
1.
Gene Gene symbol Gene ID Fold change P-value Gene regulation by LPS
2
Intestine
Immune response
Interleukin 10 IL-10 428264 0.97 0.00343 2
Toll-like receptor 3 TLR3 422720 0.95 0.00024 2
Toll-like receptor 2 precursor TLR2 -2 769014 0.96 0.00036 2
Zinc finger CCCH-type containing 15 ZC3H15 423992 0.95 0.00012 2
29–59-oligoadenylate synthetase A OAS*A 395908 0.82 0.00000 2
Gallinacin-1 alpha Gal-1 395841 0.96 0.00013 2
Metabolism
Phosphopyruvate hydratase ENO2 395689 0.93 0.00434 2
3-hydroxy-3-methylglutaryl-CoA
reductase
HMGCR 395145 0.95 0.00338 2
Others
Secreted protein acidic cysteine-rich SPARC 386571 1.04 0.01425 +
Myosin, heavy chain 11, smooth muscle MYH11 396211 1.10 0.00015 +
Actin alpha 2, smooth muscle, aorta ACTA2 423787 0.94 0.00006 2
Myosin light polypeptide 9 regulatory MYL9 396215 1.10 0.00006 +
Iron regulatory protein 1 IRP1 373916 1.04 0.01284 +
Liver
Immune response
Interleukin 13 Receptor Alpha 2 IL13RA2 422219 0.97 0.00431 2
Signal transducer and activator of
transcription 2
STAT2 6773 1.07 0.00000 +
Putative CXCR1 isoform I and II
(IL-8 receptor)
CXCR1 430652 0.93 0.00007 2
CD3 glycoprotein CD3D 396518 0.98 0.04308 2
Metabolism
UDP Glucose Pyrophosphorylase 2 UGP2 373900 1.00 0.00492 2
Enoyl-CoA hydratase EHHADH 424877 1.10 0.00000 +
Protein phosphatase 1 PPP1R8 419564 1.06 0.00017 +
Phosphopyruvate hydratase ENO2 395689 0.91 0.00000 2
ATP citrate synthase CS 1431 1.07 0.00092 +
59-AMP-activated protein kinase
gamma-2
PRKAG2 420435 1.07 0.00001 +
Others
Deiodinase Type 2 DIO2 373903 0.94 0.00134 2
Iroquois homeobox protein 1 IRX1 374185 1.09 0.00001 +
Endothelial PAS domain protein 1 EPAS1 395596 1.10 0.00033 +
Potassium voltage-gated channel
shaker-related subfamily No 3
KCNA3 404303 1.13 0.00000 +
Skeletal muscle
Metabolism
6-phosphofructokinase (PFK-1) PFKM 374064 0.95 0.00058 2
Others
Atrial natriuretic factor precursor NPPA 395765 1.03 0.00417 +
1Hosts fed MOS: LPS-challenged v/s non-challenged controls; The complete raw data have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.
nlm.nih.gov/projects/geo (accession no. GSE28959).
2+: up-regulated genes by LPS; 2: down-regulated genes by LPS.
doi:10.1371/journal.pone.0030323.t003
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1.
Gene Gene symbol Gene ID Fold change P-value
Gene regulation by
LPS
2
Intestine
Immune response
Interleukin 3 IL-3 474356 1.04 0.00404 +
Toll-like receptor 3 TLR3 422720 1.03 0.01264 +
29–59-oligoadenylate synthetase A OAS*A 395908 1.13 0.00000 +
Metabolism
Phosphoenolpyruvate carboxykinase 1 PEPCK 396458 1.12 0.00002 +
Phosphopyruvate hydratase ENO2 395689 0.94 0.01255 2
3-hydroxy-3-methylglutaryl-CoA reductase HMGCR 395145 0.95 0.00369 2
Others
Myosin, heavy polypeptide 7, cardiac muscle MYH7 395350 1.03 0.04746 +
Myosin, heavy chain 11, smooth muscle MYH11 396211 0.92 0.00094 2
Atrial natriuretic factor precursor NPPA 395765 1.03 0.00679 +
Iron regulatory protein 1 IRP1 373916 0.96 0.02641 2
Liver
Metabolism
ATP citrate lyase ACLY 395373 1.04 0.04584 +
Phosphopyruvate hydratase ENO2 395689 1.05 0.00869 +
Malic enzyme 1 ME 374189 1.06 0.01385 +
ATP citrate synthase CS 1431 0.96 0.03024 2
Skeletal muscle
Metabolism
6-phosphofructokinase (PFK-1) PFKM 374064 0.95 0.00246 2
Others
Atrial natriuretic factor precursor NPPA 395765 1.03 0.00416 +
1Hosts fed antibiotic (VIRG): LPS-challenged v/s non-challenged controls; The complete raw data have been deposited in the Gene Expression Omnibus (GEO) database,
www.ncbi.nlm.nih.gov/projects/geo (accession no. GSE28959).
2+: up-regulated genes by LPS; 2: down-regulated genes by LPS.
doi:10.1371/journal.pone.0030323.t004
Figure 1. RT-qPCR validation of microarray data. LPS up-regulated liver ACLY, ME and FAS among VIRG-fed hosts (A). But, LPS down-regulated
these genes in MOS- than VIRG-fed host (B). Intestinal PEPCK was up-regulated among control hosts fed MOS (C), and by LPS among VIRG-fed hosts
(D). Data are presented as mean 6 SEM (n=6). *, P,0.01 by Scheffe’s t test.
doi:10.1371/journal.pone.0030323.g001
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biosynthesis by up-regulating PRKAG2. Liver KCNA3 was up-
regulated in the absence of high glucose influx. Indeed, these
findings are very similar to those observed when comparing MOS-
fed hosts in the LPS-challenged and non-challenged control
groups.
Real-time quantitative PCR and liver metabolite
measurements
To confirm our microarray data, we performed quantitative
RT-qPCR analysis on three differentially expressed genes, and
measured concentrations of specific liver metabolites. Figure 1
and Tables 2, 4 and 5 show that PEPCK, ACLY and ME
expression patterns correlated strongly with microarray results.
Moreover liver citrate and pyruvate levels were in agreement with
gene expression results (Figure 2). FAS, not present on the array
utilized in this study, expression (Figure 1) was determined by
RT-qPCR. All RT-qPCR efficiency (E) values were in between
93 to 100%.
Discussion
Molecular events underlying late inflammation and subsequent-
ly nutrient mobilization, in response to pathogens or antigens, are
still not clear. Interestingly, at 24 h post-LPS challenge, micro-
array results revealed that innate immune responses were
principally mediated by IL-3, a pro-inflammatory cytokine that
has received little scientific investigations, together with other
innate immune mediators (Table 1). Few studies reported IL-3 as
playing key roles in linking innate and adaptive immunity. IL-3 is
critical for the differentiation of monocytes into dendritic cells, and
contributes in proliferation and survival of dendritic cells [40];
dendritic cells are involved in Th cell response. While IL-1 and IL-
6 were consistently up-regulated during intense inflammatory
responses in poultry [41] and mice [42], here we report that these
Table 5. Genes identified as differentially expressed due to LPS between MOS- and antibiotic-fed hosts
1.
Gene Gene symbol Gene ID Fold change P-value Gene regulation by MOS
2
Intestine
Immune response
Interleukin 3 IL-3 474356 1.03 0.00871 +
Interleukin 10 IL-10 428264 0.96 0.00028 2
Toll-like receptor 3 TLR3 422720 0.96 0.00053 2
Zinc finger CCCH-type containing 15 ZC3H15 423992 0.96 0.00100 2
29–59-oligoadenylate synthetase A OAS*A 395908 0.84 0.00000 2
Gallinacin-1 alpha Gal-1 395841 0.98 0.03227 2
Others
Actin alpha 2 smooth muscle aorta ACTA2 423787 0.94 0.00017 2
Heat shock 10 kDa protein 1 HSPE1 395948 0.92 0.00756 2
Liver
Immune response
Signal transducer and activator of
transcription 2
STAT2 6773 1.03 0.02089 +
Metabolism
UDP Glucose Pyrophosphorylase 2 UGP2 373900 0.92 0.00009 2
ATP citrate lyase ACLY 395373 0.93 0.00017 2
Phosphopyruvate hydratase ENO2 395689 0.91 0.00000 2
Malic enzyme 1 ME1 374189 0.92 0.00012 2
ATP citrate synthase CS 1431 1.11 0.00000 +
59-AMP-activated protein kinase
gamma-2
PRKAG2 420435 1.05 0.00290 +
Others
Iroquois homeobox protein 1 IRX1 374185 1.06 0.00268 +
Endothelial PAS domain protein 1 EPAS1 395596 1.09 0.00158 +
Potassium voltage-gated channel
shaker-related subfamily No 3
KCNA3 404303 1.07 0.00045 +
Skeletal muscle
Others
NK2 transcription factor related
locus 5
NKX2-5 396073 1.14 0.00000 +
1LPS-challenged hosts: MOS-fed chickens v/s VIRG-fed chickens; The complete raw data have been deposited in the Gene Expression Omnibus (GEO) database, www.
ncbi.nlm.nih.gov/projects/geo (accession no. GSE28959).
2+: up-regulated genes by MOS; 2: down-regulated genes by MOS.
doi:10.1371/journal.pone.0030323.t005
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during late inflammation. These results evidenced that inflamma-
tion is a time-dependent biological immune reaction, regulated by
different immune mediators. Most interestingly, our results
revealed that dietary MOS modulated innate immune responses
and nutrient metabolisms differently than VIRG.
Our finding that MOS increased immune responses of non-
challenged control hosts, but here principally mediated by
intestinal IL-3, is consistent with published data [43-45], thereby
revealing its inherent immune-stimulatory properties. Although
the mechanism by which MOS inherently stimulates immunity is
unclear, it may be associated with the antigenic properties of yeast
cell walls. In contrast, VIRG did not confer such immune
stimulatory effects because antibiotics lack antigenic properties.
During immune stimulation, an energy-demanding biological
process, and the consequential reduction in feed intake, the host’s
metabolic activities were coordinately regulated to increase energy
availability for metabolism. Liver gluconeogenesis, involving
muscle catabolism, usually occurs during intense inflammation
and starvation [12]. However, here, we observed that gluconeo-
genesis occurred only in the intestines. Additionally, during the
process of glucose synthesis, the preferential utilization of amino
acids from ingested feed spared skeletal muscle catabolism.
Glucose, mobilized to the liver, was then rapidly metabolized via
increased glycolytic activities to meet host’s elevated energy
demands during the inflammatory response (summarized in
Figure 3). Nevertheless, as previously reported [6], [46], MOS’s
immune-stimulatory effects did not profoundly mobilize glucose
and had no detrimental effects on feed intake or growth.
Both LPS and MOS triggered elevated innate immune
responses and glucose mobilization. However, our results that
none of the pro-inflammatory cytokines were up-regulated due to
continual MOS intake followed by LPS challenge (Tables 3 and
S1, S2, S3) revealed that MOS counteracted LPS’s detrimental
effects on immunity. We also observed that energy demands of
hosts fed MOS were sufficiently met by increased TCA cycle-
derived energy. Contrastingly, VIRG failed to counteract or
reduce LPS’s inflammatory effects, as indicated by increased IL-3
expression (Table 4). The higher energy demands of VIRG hosts
necessitated glucose mobilization through intestinal gluconeogen-
esis and increased liver glycolytic activities. Based on these
findings, we conclude that dietary MOS helped terminate LPS-
induced inflammation earlier than VIRG. This beneficial effect of
MOS may be explained by its inherent immune-stimulatory
properties that caused mild immune stimulation, thereby ‘arming’
the body’s defense mechanisms to rapidly and efficiently clear the
endotoxin.
However, increased TCA activities surprisingly occurred among
hosts fed MOS despite their reduced glycolytic activities. Although
fatty acid and cholesterol synthesis genes are coordinately down-
regulated during LPS-triggered systemic inflammation [47], we
observed increased liver de novo fatty acid synthesis among hosts fed
VIRG despite increased intestinal gluconeogenesis and liver
glycolysis. Generally, fatty acid synthesis, which converts excess
energy into energy reserves, occurs only when dietary carbohy-
drate intake exceeds immediate energy requirements. But, we
observed a reduction in feed intake due to LPS challenge. Because
inflammation is a dynamic biological immune reaction, molecular
events at 24 h post-LPS challenge are a consequence of earlier
immunological events. To help explain these apparently conflict-
ing observations, we will briefly consider nutrient mobilization
during intense inflammation. Whereas glycogenolysis and gluco-
neogenesis are frequently reported during intense inflammation,
significant mobilization and catabolism of glucose may have
significantly increased liver glucose and its glucose metabolites,
including acetyl Co-A, pyruvate and citrate, levels in both MOS-
and VIRG-fed hosts. In the absence of innate immune responses
at 24 h post-LPS challenge, increased activity of CS, a key enzyme
involved in TCA cycle, revealed that energy demands of MOS-fed
hosts were mainly derived from liver glucose/glucose metabolites
that accumulated earlier. Evidently, intestinal gluconeogenesis and
liver glycolysis were not necessary and repressed (summarized in
Figure 4).
In VIRG-fed hosts, however, elevated innate immune responses
at 24 h post-LPS challenge required higher energy. Insufficient
energy derived from accumulated liver glucose/glucose metabolites
Figure 2. Concentrations of liver metabolites. Among VIRG-fed hosts, LPS reduced liver citrate, but increased pyruvate levels (A). However,
higher citrate and lower pyruvate levels were observed in liver of LPS-challenged hosts fed MOS than VIRG (B). Data are presented as mean 6 SEM
(n=6). *, P,0.05, **, P,0.01 by Scheffe’s t test.
doi:10.1371/journal.pone.0030323.g002
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intestinal gluconeogenesis and liver glycolysis, respectively. Howev-
er, as evidenced by ACLY up-regulation, exceptionally high liver
citrate levels, which accumulated during intense inflammation,
triggered CS down-regulation. Citrate is well recognized as a potent
allosteric negative-feedback inhibitor of CS activity and plays a
crucial role in liver metabolic activities. Evidently, to rapidly
catabolize and deplete the accumulated liver cytosolic citrate after
its efflux from the mitochondria where it is synthesized, (i) ACLY up-
regulation generated high acetyl Co-A levels, (ii) ME up-regulation
increased liver NADPH concentrations, (iii) whereas FAS up-
regulationsynthesized palmitate, the majorfattyacid thatultimately
yields long fatty acid chains, from acetyl Co-A, NADPH and
malonyl Co-A, which is synthesized from acetyl Co-A by acetyl Co-
A carboxylase (summarized in Figure 5). ACLY, ME and FAS are
key lipogenic enzymes that convert liver cytoplasmic citrate into
fatty acids. The preferential acetyl Co-A and NADPH utilization in
de novo fatty acid biosynthesis mediated by ACLY, ME and FAS up-
regulations is consistent with published reports [48]. In previously
fasted and refed rats and chickens, increased liver lipogenesis was
also mediated by ACLY, ME and FAS up-regulations [49], [50].
While increased glucose mobilization and decreased fatty acid
synthesis have frequently been reported during intense inflamma-
tion [47], [51], here we report that the liver rapidly metabolized
citrate into fatty acids to restore its citrate homoeostatic level during
late inflammation in addition to glucose mobilization for body
energy requirements.
In agreement with O’Hea and Leveille [52], we observed that
livers in chickens derived most of the NADPH required for fatty
acid synthesis from the ME reaction, whereas livers in rats
obtained about 65% of NADPH from the pentose phosphate
pathway [53]. Collectively, these findings indicate that significantly
more glucose was mobilized from the intestine and more glucose
metabolites accumulated in the liver of VIRG hosts during the
period of intense inflammation than MOS-fed hosts, and that
VIRG failed to terminate innate immune responses earlier. But,
when challenged with LPS, we observed an elevation in innate
immune responses, principally mediated by intestinal IL-3, among
hosts fed MOS than VIRG. Although these results were not
surprising considering the additive immune-stimulatory effects of
MOS and LPS, no major nutrient mobilization processes occurred
among LPS-challenged hosts fed MOS (summarized in Figure 6).
TCA-derived energy from high liver glucose and glucose
metabolites which accumulated earlier than 24 h of LPS challenge
was sufficient to meet energy demands of the hosts fed MOS.
Livers and kidneys are well-recognized gluconeogenic organs in
humans and mice [54], [55]. Whereas the intestine is equivocally
reported as a gluconeogenic organ in mice [56], [57], we are
among the first to demonstrate that the chicken small intestine, but
not skeletal muscles, is also a gluconeogenic organ that was
regulated by PEPCK. We have discussed the increased intestinal
gluconeogenesis at 24 h post-LPS challenge. Given that MOS and
VIRG are not absorbed across the intestinal epithelium, these
macromolecules produce localized effects in the intestines.
Figure 3. Schematic illustration of the effects of MOS versus VIRG on glucose metabolism in control hosts. (i) MOS increased intestinal
gluconeogenesis by up-regulating PEPCK; (ii) the high glucose influx into the liver was rapidly metabolized by glycolysis as mediated by ENO2 up-
regulation; (iii) TCA-derived energy from glycolytic substrates, down-regulated ME and EHHADH which reduced fatty acid synthesis and b-oxidation,
respectively.
doi:10.1371/journal.pone.0030323.g003
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mucosal immunity and systemic immunity. This is the first study
demonstrating that MOS can beneficially modulate innate
immunity and nutrient metabolism during late systemic inflam-
mation.
In summary, late inflammation was principally modulated by
IL-3. In contrast to antibiotics like VIRG, MOS elicited several
beneficial responses: (i) terminated Salmonella LPS-induced system-
ic inflammation earlier, presumably due to its inherent intestinal
innate immune-stimulatory properties; and (ii) reduced the
magnitude of glucose mobilization. Therefore, this study poten-
tiates the use of natural immuno-modulators, such as a MOS, to
attenuate Salmonella-induced systemic inflammation both among
human and animal hosts, and without posing the risk of antibiotic-
resistance development.
Materials and Methods
Chickens, experimental diets and LPS challenge
Hatched chicks (Cobb 500 broilers) were raised in two groups
(n=64/group). In each bird group (8 cages/diet), half was fed a
diet containing MOS (2 kg/ton BioMosH; Alltech Inc., Nicholas-
ville, KY) or virginiamycin (16.5 mg/kg), as described [46]. To
induce an acute inflammatory response, group 1 hosts (n=64)
were injected i.p. with 3 ml of Salmonella Typhimurium LPS
(100 mg LPS/L, Sigma-Aldrich, ON, Canada) whereas group 2
control hosts were saline-injected at 14 d of age. All animal
procedures were approved by the McGill Animal Care Committee
(protocol number 5399). All hosts had free access to feed and
water.
Bodyweight, feed intake and body temperature
measurements
All non-challenged control (saline-injected) and LPS-challenged
hosts were individually weighed at 0 (initial BW), 12, 24 and 48 h
post-injection to determine BW gain relative to initial BW.
Average feed consumption of chickens was calculated at similar
time points. Body temperatures were recorded after 0, 2, 4, 6, 8,
12, 24 and 48 h of saline or LPS injection using a thermocouple
rectal probe thermometer (Physitemp Instruments Inc., Clifton,
NJ).
Liver weights and tissue samples collection
Chickens (n=8/diet/group) were randomly euthanized at 12,
24 and 48 h post-injection and liver weights of respective chickens
were expressed relative to their final BW. At 24 h after saline and
LPS injections, liver, intestine (jejunum) and skeletal muscle (breast
meat) samples (n=6 /diet/group) were immediately snap frozen
in liquid nitrogen, and stored at 280uC for later RNA extraction.
Figure 4. Schematic illustration of MOS effects on glucose metabolism between control and LPS-challenged hosts. (i) LPS triggered no
major intestinal metabolic activities; (ii) in absence of glucose mobilization, liver glucose uptake and transport were repressed by DIO2 down-
regulation and KCNA3 up-regulation, respectively; (iii) glycolysis and glycogen synthesis were coordinately reduced by ENO2 and UGP2 down-
regulation, respectively; (iv) CS up-regulation increased TCA-derived energy from high liver pyruvate; (v) PRKAG2 up-regulation inhibited fatty acid
and cholesterol biosynthesis.
doi:10.1371/journal.pone.0030323.g004
Yeast Cell Wall Anti-Inflammatory Effects
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30323Microarray analysis
After 24 h, total RNA was extracted from liver, intestine
(jejunum) and skeletal muscle (breast) tissues using Trizol reagent
and Purelink RNA Mini Kit (Invitrogen). Isolated total RNA was
quantified on the basis of its absorption at 260 nm using a
NanodropH ND-1000 spectrophotometer (NanoDrop Technolo-
gies, Wilmington, DE), and visualized on an agarose gel to check
quality. RNA was retrotranscribed into Cy3 or Cy5 aminoallyl
labelled cDNA and hybridized onto chicken-specific focused
oligonucleotides microarrays. The microarray platform used
(accession number GPL13457) and data files (accession number
GSE28959) are registered at the MIAME compliant National
Centre for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO) archive (http://ncbi.nlm.nih.gov/projects/geo).
Briefly, 70mers chicken-specific oligonucleotides, obtained from
Operon Biotechnologies Inc. (Germantown, MD), were spot
printed on UltraGAPS Amino-Silane Coated Slides (Corning
Inc., Acton, MA) as described [58]. Each oligonucleotide sequence
(probe) was replicated 12 times per array.
cDNA labeling and microarray hybridization
A total of 12 microarrays was used per tissue and chicken group
(n=6/diet) in a 262 factorial design and complete interwoven
loop arrangement (Figure S5; [59]). First, RNA was retro-
transcribed into aminoallyl labelled cDNA using the ChipShot
Indirect Labelling and Clean-Up System Kit (Promega, Madison,
WI) and Cy3 or Cy5 fluorescent dye (Amersham Biosciences
Corp., Piscataway, NJ) according to the manufacturer’s recom-
mendations. Reverse transcription was carried out at 42uC for 2 h,
followed by RNase H digestion for 15 min at 37uC. Briefly, a
reactive amine derivative of 5-(3-aminoallyl)-29-deoxyuridine 59-
triphosphate was incorporated during reverse transcription.
Subsequent to reverse transcriptase reaction, succinimidyl esters
of Cy3 or Cy5 were covalently bonded to aminoallyl-labelled
cDNAs. Cy-3 and Cy-5 labelled cDNA were then purified,
combined and hybridized to the array for 24 h in darkness by
making use of the Pronto Plus! Microarray Hybridisation Kit
(Corning Inc., NY).
Microarray data analysis
Hybridized arrays were scanned twice at 65% (Cy3) and 50%
(Cy5) laser power using a ScanArray GX PLUS Microarray
Scanner (PerkinElmer Life and Analytical Sciences, Shelton, CT)
to obtain Cy3:Cy5 intensity ratios of labelled cDNA hybridized to
complementary oligonucleotide sequences on the array. Spot
intensity data were extracted using the ScanAlyze Software
(Standford University, Standford, CA) and analyzed using the
JMP Genomics software (SAS Institute Inc., Cary, NC). Data were
log2 transformed prior to normalization by using locally weighted
regression and smoothing, first within array (ratio analysis) and
then across arrays (Lowess normalization). Normalized data were
monitored by distribution analysis of the transformed data. Finally,
Figure 5. Schematic illustration of VIRG effects on glucose metabolism between control and LPS-challenged hosts. (i) LPS increased
intestinal gluconeogenesis by up-regulating PEPCK; (ii) mobilized glucose increased liver glycolytic activities through ENO2 up-regulation; (iii) CS
down-regulation reduced utilization of glycolytic substrates by the TCA cycle for energy; (iv) ACLY, ME and FAS up-regulations increased liver fatty
acid biosynthesis from high liver citrate.
doi:10.1371/journal.pone.0030323.g005
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way ANOVA, as described [60]. Expression values were modeled
as: Yijklm=m+Ai+Cj+Dk+Il+DIkl+eijklm, where m represents the
overall mean value, Ai: random effect for arrays (i=1, 2…..12), Cj:
main effect of Cy-dye (j=Cy-3 or Cy-5), Dk: main effect of diet
(k=MOS or VIRG), Il: main effect of injection (l=saline or LPS),
and DIkl: interaction effect between diet and injection, and eijklm:
random error. Mean intensities were tested using the false
discovery rate (FDR) multiple comparison t test and differentially
expressed genes were declared at P,0.05. Finally, for each
pairwise comparison, significantly different genes were filtered
based on their mean intensity values to determine up- or down-
regulated genes due to diet, injection and diet*injection.
Real-time quantitative PCR analysis
Real-time quantitative PCR (RT-qPCR) was used for validation
of differential gene expressions observed in microarrays. Total
RNA was retrotranscribed into cDNA by using 1 mg total RNA
and iScript cDNA Synthesis Kit (Bio-Rad, ON, Canada),
following the manufacturer’s instructions. RT-qPCR was per-
formed using the Bio-Rad CFX384 RT-qPCR Detection System,
SsoFast Evagreen Supermix (Bio-Rad) and primer-set sequences
(Table 6). RT-qPCR reactions were performed at 95uC for 5 min,
followed by 39 cycles of 95uC for 15 s and 60uC for 30 s. A
melting curve program was included at the end of each RT-qPCR
to verify presence of a unique product. Relative intestinal (PEPCK)
and liver (ACLY, ME, CS and FAS) gene expression levels were nor-
malized to GAPDH or beta-2 microglobulin, respectively. The expression
stability of the reference genes were tested using the geNorm software
(available at: http://medgen.ugent.be/,jvdesomp/genorm/). Sam-
ples were analyzed in technical duplicates, and differential gene
expressions were determined using the comparative standard curve
method.
Liver metabolites measurements
Liver citrate and pyruvate levels were measured by specific
enzymatic reactions using the Citrate and Pyruvate Assay Kits
(BioVision, CA, USA), following the manufacturer’s instructions
with few modifications. Briefly, 0.5 g of liver tissues were
homogenized completely by sonication in 700 mL of respective
buffer solutions and then centrifuged at 15,000 g for 10 mins to
remove cell debris. After the supernatant was deproteinized using
the Deproteinizing Sample Preparation Kit (BioVision), a 100 mL
sample volume was used for analysis. Reaction mix was prepared
without buffer dilution.
Statistical analysis
Except for microarray data, all data were analyzed as a two-way
ANOVA and a 262 factorial arrangement to determine the main
effects of diet and injection, and their interaction effects by using
Figure 6. Schematic illustration of LPS effects on glucose metabolism between MOS- and VIRG-fed hosts. (i) LPS caused no major
intestinal metabolic activities in MOS-fed hosts; (ii) in absence of liver glucose mobilization, KCNA3 was up-regulated, whereas ENO2 and UGP2 down-
regulation reduced glycolysis and glycogen synthesis, respectively; (iii) CS up-regulation increased TCA cycle-derived energy from high liver pyruvate;
(iv) ACLY, ME and FAS down-regulations inhibited liver fatty acid biosynthesis; whereas PRKAG2 up-regulation inhibited fatty acid and cholesterol
biosynthesis.
doi:10.1371/journal.pone.0030323.g006
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bodyweight, liver weight and body temperature data, a Nested
Model Design was also employed with cages nested within
diet*injection, as follows: Yijkl=m+Dieti+Injectionj+Dieti*Injec-
tionj+Cageijk+eijkl, where m represents the overall mean value,
Dieti: fixed effect of diet (i=MOS or VIRG), Injectionj: fixed
effect of injection (j=saline or LPS), Dieti * Injectionj: interaction
effect between diet and injection, Cageijk: random effect of cage
nested within diet*injection (k=1,2,…8), and eijkl: random error.
Differences among treatment means were tested using Scheffe’s t
test and statistical significance declared at P,0.05.
Supporting Information
Figure S1 Innate immune-stimulatory effects of LPS caused
elevation in body temperatures. Antibiotic (VIRG)- and MOS-fed
hosts were injected i.p. with LPS. At 0, 2 and 48 h after injection,
body temperatures were not different between LPS-challenged
and non-challenged control (saline) hosts (A), or between VIRG-
and MOS-fed hosts within the LPS-challenged or control group,
respectively (B), or between hosts fed VIRG and MOS (C).
However, in comparison with control hosts, LPS significantly
increased (P,0.05) body temperatures at 4, 6, 8, 12 and 24 h post-
injection (A). But, such increase in body temperatures were not
observed between VIRG and MOS hosts within the LPS-
challenged or control group, respectively (B), or between VIRG-
and MOS-fed hosts irrespective of injection type (C). Results are
expressed as mean 6 SEM. Supercripts: (a,b) denote statistical
differences among treatment means at a particular time point,
P,0.05, Scheffe’s multi-comparison t-test.
(PDF)
Figure S2 The effects of LPS injected i.p. on feed intake in
antibiotic- (VIRG) and MOS-fed hosts. LPS significantly reduced
feed intake(P,0.05)at 12 h post-injection(A). However,feed intake
was not different between hosts fed the VIRG and MOS diet (B), or
between VIRG and MOS hosts within the LPS-challenged or non-
challenged control (saline) group, respectively (C). At 24 and 48 h
post-injection, feed intake was not different between LPS and
control hosts (A), hosts fed the VIRG and MOS diet (B), or between
VIRG and MOS hosts within the LPS-challenged or control group,
respectively (C). Results areexpressedas mean 6 SEM. Supercripts:
(a,b) denote statistical differences among treatment means at a
particular time, P,0.05, Scheffe’s multi-comparison t-test.
(PDF)
Figure S3 The effects of LPS injected i.p. on bodyweight (BW)
gain in antibiotic- (VIRG) and MOS fed hosts. LPS significantly
reduced BW (P,0.05) after 12, 24 and 48 h of injection (A). In
contrast to MOS-fed hosts, those fed VIRG grew faster (P,0.05)
at 48 h only (B). But, BW gain was not different between VIRG
and MOS hosts within the LPS-challenged or non-challenged
control (saline) group, respectively (C). Results are expressed as
mean 6 SEM. Supercripts: (a,b) denote statistical differences
among treatment means at a particular time point, P,0.05,
Scheffe’s multi-comparison t-test.
(PDF)
Figure S4 The effects of LPS injected i.p. on liver weights of
antibiotic- (VIRG) and MOS fed hosts. LPS significantly increased
(P,0.05) liver weights at 12 and 24 h post-injection, but not after
48 h (A). However, at all times, liver weights were not different
between hosts fed the VIRG and MOS diet (B), or between VIRG
and MOS hosts within the LPS-challenged or non-challenged control
(saline) group, respectively (C). Results are expressed as mean 6SEM.
Supercripts: (a,b) denote statistical differences among treatment
means at a particular time, P,0.05, Scheffe’s multi-comparison t-test.
(PDF)
Figure S5 Schematic of the 262 factorial experimental design in
an interwoven loop arrangement for each tissue (liver, intestine or
skeletal muscles). Diet6Injection is denoted as VC (VIRG6non-
challenged control hosts), VL (VIRG6LPS-challenged hosts), BC
(MOS6non-challenged control hosts), and BL (MOS6LPS-
challenged hosts). Each arrow represents an array (total: 12)
consisting of 2 aminoallyl labelled cDNA, either Cy-3 or Cy-5.
(PDF)
Table S1 Fold change and P values of gene expressions due to
prebiotic and antibiotic in intestinal tissues of non-challenged
control and LPS-challenged birds.
(XLSX)
Table S2 Fold change and P values of gene expressions due to
prebiotic and antibiotic in liver tissues of non-challenged control
and LPS-challenged birds.
(XLSX)
Table S3 Fold change and P values of gene expressions due to
prebiotic and antibiotic in skeletal muscle tissues of non-challenged
control and LPS-challenged birds.
(XLSX)
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Table 6. Primers-set sequences used to analyze gene expression by quantitative PCR.
Gene Forward primer
a Reverse primer
a
Amplicon
length (bp)
PubMed Accession
No.
PEPCK CTGCTGGTGTGCCTCTTGTA TTCCCTTGGCTGTCTTTCC 259 NM_205471
ACLY GGCGTGAATGAACTGGCTAAC TAGTCTTGGCATAGTCATAGGTCTGTTG 79 NM_001030540
ME TGCCAGCATTACGGTTTAGC CCATTCCATAACAGCCAAGGTC 175 NM_204303
FAS TGAAGGACCTTATCGCATTGC GCATGGGAAGCATTTTGTTGT 96 NM_205155
GAPDH TGCCATCACAGCCACACAGAAG ACTTTCCCCACAGCCTTAGCAG 123 NM_204305
Beta-2
microglobulin
AAGGAGCCGCAGGTCTA CTTGCTCTTTGCCGTCATAC 151 Z48921
aSequences are indicated from 59 end to 39 end of oligonucleotides.
doi:10.1371/journal.pone.0030323.t006
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